Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Introduction: In patients with hematological malignancies, COVID-19 is considered to be associated with a high risk of severe morbidity and mortality. While anti-COVID-19 vaccination of such patients has become the standard of care, many of them fail to generate protective serological response due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dann, Eldad J, Inbar, Tsofia, Mashiach, Tania, Eisa, Jamela, Harlev, Shimrit Ringelstein, Horowitz, Netanel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
624.Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701910/
http://dx.doi.org/10.1182/blood-2021-149379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701910/
http://dx.doi.org/10.1182/blood-2021-149379

Ejemplares similares